Floatz logo

Ipilimumab

Metastatic Kidney Carcinoma

Fondazione Policlinico Universitario Agostino Gemelli IRCCSmonoclonal_antibodyPhase 4 / ApprovedActive
BB
69/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
55/ 100
Competitive Position
89/ 100

Competitive context

41 Active assets in the Metastatic Kidney Carcinoma cohort.

Asset / SponsorPhaseRating
Nivolumab
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Phase 4BBB
Bms-907351
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Phase 4BB
Pembrolizumab
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Phase 4BB
LENVATINIB
Gustave Roussy, Cancer Campus, Grand Paris
Phase 3B
(±)-1-BUTYL-2',6'-PIPECOLOXYLIDIDE MONOHYDROCHLORIDE
Wake Forest University Health Sciences
Phase 3B

View all 50 →

Same molecule, other indications

Ipilimumab is also rated in:

metastatic neoplasmDormant
BB
Indicative ·
71 / 100
View asset →
Clinical Stage IV Cutaneous Melanoma AJCC v8Dormant
BB
Indicative ·
69 / 100
View asset →
cutaneous melanomaDormant
BB
Indicative ·
69 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →